Where now for pharma?
Steve How and Paul Midgley, of Wilmington Healthcare, explore the diverse needs of local NHS health economies as they respond to the Long Term Plan’s demands for joined-up, holistic care
Following months of heated debate in parliament
Meanwhile, our cover feature this month (p16) considers
Steve How and Paul Midgley, of Wilmington Healthcare, explore the diverse needs of local NHS health economies as they respond to the Long Term Plan’s demands for joined-up, holistic care
The prospect of Brexit-related drugs shortages is looming, although a snarl-up may yet be avoided
James Huang and Stephen Huang consider the promise and risk of gene therapy
Richard McAleavy considers what autonomous cars can teach digital healthcare about building engagement
Marcus Vass and Jane Whitcombe consider the future for digital health and some of the key tech collaborations that will start to make a difference to patients over the next year
Margaret Kyle takes a look at excessive pricing in the pharma industry
In its finest hours, the bond between patients and pharma can move mountains, defy disease and change the course of history
How to orchestrate true value from customer engagement and achieve brand launch success
Sheena Linehan takes a look at the recent legal cases impacting the life sciences landscape
We talk to Eric Hughes about his role as Novartis’ global development unit head of Immunology, Hepatology and Dermatology
Tracy Nesbit has experienced insomnia all her life. She tells PharmaTimes her story